SITC 2026 recap from a melanoma and sarcoma oncologist: next-gen TIL, dual bispecifics, cell therapy in sarcoma, and why infusion timing may matter.
Immunotherapy
Unleash the power of your body’s immune system in the fight against cancer with our “Immunotherapy” subcategory. Delve into the realm of groundbreaking treatments that empower your immune system to recognize and combat cancer cells. Explore the latest advances in immunotherapy, from checkpoint inhibitors to CAR-T cell therapies, and learn how they are revolutionizing the landscape of cancer treatment. Join us on a journey to understand how harnessing your body’s natural defenses is paving the way for more targeted and effective therapies in the fight against cancer.
For the first time, an individualized mRNA cancer vaccine has beaten standard-of-care immunotherapy in a randomized phase 3 trial. INTerpath-001 showed a 42% reduction in recurrence risk and an 8-point absolute gain in freedom from distant metastasis in resected stage IIB–IV melanoma — with essentially no added toxicity. Here is what the data showed, and the four questions I think determine how we use it well.
After two rejections, the FDA approved a new melanoma therapy that finally reaches beyond the skin — into the liver, into the lungs. Here’s why the third try worked.
Details once dismissed as trivial—like timing—can quietly reshape cancer care.
Sometimes restraint is the wiser choice — half of patients are cured with PD-1 alone.
When immune therapy clears cancer, the real question for resectable tumors becomes: Do we still need to resect?
Five groundbreaking trials from the ASCO Plenary are transforming cancer care—ushering in biomarker-led immunotherapy across multiple disease types.
Stage IV melanoma used to be synonymous with a terminal diagnosis. For years, oncologists faced the grim reality of limited options and poor survival rates for their patients. However, the landscape has changed dramatically over the past decade. Breakthroughs in immunotherapy and clinical research have rewritten the narrative, offering hope to patients and their families. …
Colorectal cancer remains a significant global health challenge, ranking as the third most common cancer and the second leading cause of cancer-related deaths worldwide. Among metastatic colorectal cancer patients, the subset with microsatellite instability-high (MSI-H) or mismatch-repair–deficient (dMMR) tumors presents unique opportunities for immunotherapy. The recent CheckMate 8HW trial, published in the New England Journal …
Bladder cancer, particularly muscle-invasive bladder cancer (MIBC), poses significant treatment challenges due to its high recurrence rate and aggressive nature. Traditionally, neoadjuvant chemotherapy followed by surgery (radical cystectomy) has been the standard of care for cisplatin-eligible patients. However, researchers have been exploring ways to improve outcomes by incorporating immunotherapy into treatment. A recent phase 3 …